A multicenter, randomized, controlled trial of S ‐1 monotherapy versus S‐1 and interferon‐α combination therapy for hepatocellular carcinoma with extrahepatic metastases

ConclusionsOncologic outcomes in both treatment groups were favorable compared to previous reports, though there was no significant beneficial effect of adding IFN‐α to S‐1 for the treatment of HCC patients with extrahepatic metastases.

Source: Hepatology Research - January 1, 2018 Category: Internal Medicine Authors: Hiroaki Nagano, Shuntaro Obi, Etsuro Hatano, Shuichi Kaneko, Fumihiko Kanai, Masao Omata, Akihito Tsuji, Toshiyuki Itamoto, Kazuhide Yamamoto, Masatoshi Tanaka, Shoji Kubo, Koichi Hirata, Hideji Nakamura, Yoshito Tomimaru, Takeharu Yamanaka, Shinsuke Koji Tags: Original Article Source Type: research